Big Pharma Outlook 2025, An Infographic
Executive Summary
Big Pharma is poised for growth because of strong launch portfolios, the availability of high-potential pipeline assets, and a focus on high-performing markets. This outlook has been created using in-house sales forecasts from the 16 companies that form Datamonitor Healthcare's Big Pharma peer set.
Infographic: Big Pharma Outlook to 2025
[Editor’s note: For more information, see Datamonitor Healthcare’s in-depth Big Pharma Outlook report]